Of note, in the same analysis, patients with PIK3CAmut tumours that harbour a co‐occurring FGFR1 alteration experienced improved PFS upon treatment with alpelisib + FUL compared to PBO + FUL [35]. Here, FGFR1 is linked to neoplasm.